Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL

Lyell Immunopharma (NASDAQ: LYEL) presented new clinical and translational data for rondecabtagene autoleucel (ronde-cel) at ASH on Dec 7, 2025 showing high responses in large B-cell lymphoma (LBCL). In 3L+ patients (n=29 efficacy-evaluable) ronde-cel achieved a 93% ORR, 76% CR rate and median progression-free survival of 18 months. In 2L patients (n=18 efficacy-evaluable; 94% primary refractory) it showed an 83% ORR and 61% CR rate with durable CRs.

https://www.stocktitan.net/news/LYEL/lyell-immunopharma-presents-new-clinical-data-from-ongoing-trial-of-i9whlp3dt524.html